BACKGROUND: Development of brain metastasis in patients with breast carcinoma correlates with poor outcome. Identification of tumor characteristics associated with breast cancer brain metastases (BCBM) could help identify patients at risk. PATIENTS AND METHODS: We studied 209 patients with BCBM. We evaluated a panel of proteins relevant to the biology of breast carcinoma on tissue microarrays of 133 primary tumors and 56 BCBM, including paired samples from 43 patients, and correlated the findings with the clinical outcome. RESULTS: The median survival after BCBM diagnosis was 19 months (95% confidence interval, 13-23 months). Patients presenting with solitary metastasis had a significantly longer median survival than those with multiple lesions (25 versus 11 months, P ≤ 0.0001). We found no significant discordance in the expression of tested markers, but identified a possible association between the expression of basal cytokeratin CK5/6 in the primary carcinoma and the development of multiple rather than solitary brain metastases. CONCLUSIONS: Expression of antigens commonly associated with breast carcinoma does not differ significantly between the primary tumor and the corresponding brain metastases. Although no specific immunoprofile identifies breast carcinomas that develop brain metastases, we observed a possible association between CK5/6 expression in the primary tumor and multiple versus solitary BCBM.
BACKGROUND: Development of brain metastasis in patients with breast carcinoma correlates with poor outcome. Identification of tumor characteristics associated with breast cancer brain metastases (BCBM) could help identify patients at risk. PATIENTS AND METHODS: We studied 209 patients with BCBM. We evaluated a panel of proteins relevant to the biology of breast carcinoma on tissue microarrays of 133 primary tumors and 56 BCBM, including paired samples from 43 patients, and correlated the findings with the clinical outcome. RESULTS: The median survival after BCBM diagnosis was 19 months (95% confidence interval, 13-23 months). Patients presenting with solitary metastasis had a significantly longer median survival than those with multiple lesions (25 versus 11 months, P ≤ 0.0001). We found no significant discordance in the expression of tested markers, but identified a possible association between the expression of basal cytokeratin CK5/6 in the primary carcinoma and the development of multiple rather than solitary brain metastases. CONCLUSIONS: Expression of antigens commonly associated with breast carcinoma does not differ significantly between the primary tumor and the corresponding brain metastases. Although no specific immunoprofile identifies breast carcinomas that develop brain metastases, we observed a possible association between CK5/6 expression in the primary tumor and multiple versus solitary BCBM.
Authors: Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William Sperduto; Emil Lou; Ashlyn Everett; Drexell Hunter Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; James Yu; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300
Authors: C Bachmann; S Schmidt; A Staebler; T Fehm; F Fend; J Schittenhelm; D Wallwiener; E Grischke Journal: Med Oncol Date: 2014-11-30 Impact factor: 3.064
Authors: Renata Duchnowska; Rafał Dziadziuszko; Tomasz Trojanowski; Tomasz Mandat; Waldemar Och; Bogumiła Czartoryska-Arłukowicz; Barbara Radecka; Wojciech Olszewski; Franciszek Szubstarski; Wojciech Kozłowski; Bożena Jarosz; Wojciech Rogowski; Anna Kowalczyk; Janusz Limon; Wojciech Biernat; Jacek Jassem Journal: Breast Cancer Res Date: 2012-08-16 Impact factor: 6.466
Authors: Carmen Criscitiello; Fabrice André; Alastair M Thompson; Michele De Laurentiis; Angela Esposito; Lucia Gelao; Luca Fumagalli; Marzia Locatelli; Ida Minchella; Franco Orsi; Aron Goldhirsch; Giuseppe Curigliano Journal: Breast Cancer Res Date: 2014 Impact factor: 6.466